The trajectory of Viagra, formerly marketed by copyright, presents a fascinating case study for stakeholders considering the drug sector. Although its initial success and generation of vast in earnings , the exclusivity end has opened the door for generic medications, greatly reducing earnings opportunities. This change raises doubts about the long